First line of the email MUST contain NCT # and Site #.
CONTACT
Lead
Bristol-Myers Squibb
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Participants must have a primary diagnosis of schizophrenia established by a comprehensive psychiatric evaluation based on the Diagnostic and Statistical Manual of Mental Disorders⎯Fifth Edition (DSM-5) criteria and confirmed by Mini International Neuropsychiatric Interview (MINI).
Participants must have a PANSS total score between 80 and 120, inclusive.
Participants must have a CGI-S score of ≥ 4.
You may not be if
Participants must not have any primary DSM-5 disorder other than schizophrenia within 12 months before screening.
Participants must not be newly diagnosed or experiencing their first treated episode of schizophrenia.
Participants must not have any history or presence of clinically significant medical conditions.
Clareo Health | A Study to Evaluate the Efficacy and Safety of KarXT in Acutely Psychotic Japanese Adult Participants With Schizophrenia
